- Intelligent Bio Solutions (NASDAQ: INBS) expands its presence in the U.S. Forensic Market through a strategic partnership with SMARTOX.
- Over 50 Intelligent Fingerprinting Drug Screening Readers deployed, with more than 7,000 tests conducted, including 1,500+ in 2024 alone.
- INBS is pursuing FDA clearance for its opiate test system, aiming to expand into broader U.S. markets, including workplace drug testing.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) announces significant progress in the U.S. Forensic Market through its partnership with Texas-based drug screening company SMARTOX. The collaboration has resulted in the deployment of over 50 Intelligent Fingerprinting Drug Screening Readers and the completion of more than 7,000 tests, with over 1,500 conducted in 2024 alone. This reflects strong market adoption of INBS's cutting-edge fingerprint-based drug screening technology, which provides rapid, non-invasive results in less than ten minutes.
The company is actively seeking FDA clearance for its opiate test system for codeine, which would allow expansion into wider U.S. markets, including the workplace drug testing sector. The fingerprint sweat-based testing system offers a hygienic, efficient, and cost-effective method for drug screening, enhancing user experience and reducing operational complexities.
SMARTOX plays a crucial role in unlocking various forensic settings, such as corrections, drug courts, and rehabilitation centers, with an international footprint extending to Europe, Latin America, New Zealand, and Australia. The partnership aligns with INBS's mission to revolutionize drug testing through innovative, non-invasive technologies, providing potential for further growth in both current and new markets.
